BioCentury
ARTICLE | Clinical News

Actos pioglitazone: Postmarketing study data

June 20, 2011 7:00 AM UTC

Last week, FDA said it was updating the label of Actos to warn that use of the drug for >1 year may be associated with an increased risk of bladder cancer. Takeda said in a statement it is working wit...